<p>Long Noncoding RNA CDKN2B-AS1 Facilitates Lung Cancer Development Through Regulating miR-378b/NR2C2</p>

Abstract

Aim: Long noncoding RNA (lncRNA) have proved to be important regulators in various diseases. CDKN2B-AS1 was a newly identified tumor-related lncRNA, and previous studies have reported its function in laryngeal squamous cancer and osteosarcoma. However, the function and mechanism of lncRNA CDKN2B-AS1 in lung cancer are still unknown. Methods: Cell proliferation, invasion, migration and apoptosis were detected via CCK-8, transwell assay and Western blot. Bioinformatics analysis was used to predict the potential target of CDKN2B-AS1. A rescue experiment was performed to identify the relationship between CDKN2B-AS1 and miR-378b. Results: The expression of lncRNA CDKN2B-AS1 was significantly upregulated in lung cancer tissues and cell lines. Overexpression of CDKN2B-AS1 promoted cell proliferation, invasion and reduced cell apoptosis. Knockdown of CDKN2B-AS1 inhibited cell proliferation, invasion and increased cell apoptosis. Bioinformatics analysis predicted that miR-378b was the direct target. We also provided evidence that NR2C2 was the target of miR-378b. The expression of NR2C2 was significantly upregulated in lung cancer tissues and cell lines. The rescue experiment further confirmed the relationship between CDKN2B-AS1 and miR-378b. Overexpression of miR-378b completely reversed the function of CDKN2B-AS1. Conclusion: Taken together, our results comprehensively analyzed the function of CDKN2B-AS1 in lung cancer and provided a possible mechanism that CDKN2B-AS1 facilitates lung cancer development by regulating miR-378b and NR2C2. Thus, our study offers a potential therapeutic target for treating lung cancer.

Knockdown of long non-coding RNA CDKN2B-AS1 suppresses the progression of breast cancer by miR-122-5p/STK39 axis

“…Based on our data, lncRNA CDKN2B-AS1 played an oncogenic factor in breast cancer. It is consistent with the previous other studies about its role in most cancers, which indicated that CDKN2B-AS1 exerted a pro-cancer effect [ 40–42 ]. For examples, in renal clear cell carcinoma, lncRNA CDKN2B-AS1 affected the malignancy through epigenetically activating NUF2 (NUF2 Component of NDC80 Kinetochore Complex) transcription [ 16 ].…”

CDKN2B-AS1 Promotes Malignancy as a Novel Prognosis-Related Molecular Marker in the Endometrial Cancer Immune Microenvironment

“…In renal clear cell carcinoma, CDKN2B-AS1 exerts its carcinogenic activity by recruiting CREB-binding protein and three epigenetic modification complexes containing SET and MYND domains to the promoter region of the Ndc80 mitochondrial complex (NUF2) ( Xie et al, 2021 ). In lung cancer, CDKN2B-AS1 acts as a cavernous body by adsorbing miR-378b and regulating miR-378b/NR2C2 to promote cancer development ( Wang et al, 2020 ). However, the expression and role of CDKN2B-AS1 in EC remains unclear.…”

Circular RNA ZNF609 enhances proliferation and glycolysis during glioma progression by miR-378b/SLC2A1 axis

“…MiR-378b has been reported to modulate cancer progression as a tumor suppressor. It has been reported that long Noncoding RNA CDKN2B-AS1 contributes to development of lung cancer by modulating miR-378b/NR2C2 axis [ 31 ]. Meanwhile, SLC2A1 plays an essential function in the regulation of glycolysis and progression of glioma.…”